Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Vamzar Plus - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Vamzar Plus

Approved

STANDARD

Vamzar Plus

Lloyd Laboratories, Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 04d3f47dd232534a
Company: Lloyd Laboratories, Inc.
Type: Standard

Approval Details

Approval Id: 04d3f47dd232534a
Drug Approval Philippines Name: Vamzar Plus
Product Name: Vamzar Plus
Registration Number: DR-XY43598
Brand Name: Vamzar Plus
Generic Name: Losartan Potassium + Hydrochlorothiazide
Dosage Form: Fim-Coated Tablet
Dosage Strength: 50 mg/12.5 mg
Manufacturer: Lloyd Laboratories, Inc.
Trader: Ultramed Pharma Inc.
Issuance Date: 26 April 2024
Expiry Date: 06 August 2029
Pharmacologic Category: Angiotensin II Receptor Blocker
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

04d3f47dd232534a

Type

Standard

Back to Philippines FDA Approvals